# Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma

> **NCT01484626** · PHASE1,PHASE2 · TERMINATED · sponsor: **Loyola University** · enrollment: 3 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Bendamustine

## Key facts

- **NCT ID:** NCT01484626
- **Lead sponsor:** Loyola University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-05-05
- **Primary completion:** 2014-06-18
- **Final completion:** 2014-06-18
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Celgene would no longer supply lenalidomide for the study
- **Last updated:** 2018-07-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01484626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01484626, "Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01484626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*